MedPath

Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L

Overview

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis. It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea. Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions

  • Acute Pain
  • Ankylosing Spondylitis (AS)
  • Osteoarthritis (OA)
  • Primary Dysmenorrhoea
  • Rheumatoid Arthritis
  • Rheumatoid Arthritis, Juvenile
  • Severe Acute Pain

FDA Approved Products

Celecoxib
Manufacturer:Preferred Pharmaceuticals, Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2024/03/21
NDC:68788-8206
Generic drug
Manufacturer:Simcere of America, Inc.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2022/01/17
NDC:72567-001
Celecoxib
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2024/04/01
NDC:70518-3826
celecoxib
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2023/12/08
NDC:68180-399
celecoxib
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/12/08
NDC:68180-396

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath